<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659980</url>
  </required_header>
  <id_info>
    <org_study_id>S62794</org_study_id>
    <nct_id>NCT04659980</nct_id>
  </id_info>
  <brief_title>Preventing Taxane-related Peripheral Neuropathy, Pain and Nail Toxicity: A Prospective Self-controlled Trial Comparing Hilotherapy With Frozen Gloves in Early Breast Cancer</brief_title>
  <official_title>Hilotherapy vs Frozen Gloves for Preventing Taxane-related Peripheral Neuropathy, Pain and Nail Toxicity in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevention of taxane-related toxicities at the extremities is highly important for&#xD;
      patients' treatment and quality-of-life. Unlike standard cryotherapy with frozen gloves,&#xD;
      hilotherapy produces cooling at a constant temperature. Comparative data with frozen gloves&#xD;
      are unavailable. This prospective self-controlled study explores the efficacy of hilotherapy&#xD;
      at the right hand and foot compared to frozen gloves at the left in patients with early&#xD;
      breast cancer treated with weekly paclitaxel 80 mg/m² or three-weekly docetaxel 75 mg/m².&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">November 20, 2020</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>any-grade incidence of side-effects at the extremities (peripheral neuropathy, pain, nail toxicity)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>grade 2+ side-effects at the extremities (peripheral neuropathy, pain, nail toxicities)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>hilotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>frozen gloves</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hilotherapy</intervention_name>
    <description>continuous cooling of hands and feet at a constant temperature</description>
    <arm_group_label>hilotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>frozen gloves</intervention_name>
    <description>cooling of hands and feet using frozen gloves</description>
    <arm_group_label>frozen gloves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  adult (≥18 years) patients with breast cancer&#xD;
&#xD;
          -  treated with weekly paclitaxel 80 mg/m² (12 cycles) or three-weekly docetaxel 75 mg/m²&#xD;
             (4 or 6 cycles) in an adjuvant or neo-adjuvant setting.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  peripheral neuropathy or pain in the extremities at baseline, regardless of whether&#xD;
             this was related to a prior chemotherapy treatment or another condition&#xD;
&#xD;
          -  Raynaud's phenomenon, cold intolerance or any condition to the nails or peripheral&#xD;
             blood vessels that could pose a risk to the compliance with the study interventions&#xD;
&#xD;
          -  insufficient understanding of the Dutch language for self-reporting the side-effects&#xD;
             under investigation&#xD;
&#xD;
        Patients were excluded from the analysis if they received less than two thirds of planned&#xD;
        treatment cycles, for other reasons than the side-effects investigated in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

